



Supplementary Table 1 Outcomes of exit-site infection and catheter-related bloodstream infection

Variables	Mangostin (N=33)	Placebo (N=33)	p-value
Exit site infection (%)	2 (6.1)	4 (12.1)	0.392
Episode per 1000 catheter – days (95% confidence interval)	2.12 (0.53, 8.49)	4.84 (1.82, 12.9)	0.309
Relative risk (95% confidence interval)	0.5 (0.1, 2.54)		
Catheter-related bloodstream infection (%)	1 (3.0)	5 (15.2)	0.087
Episode per 1000 catheter -days (95% confidence interval)	1.06 (0.15, 7.54)	6.05 (2.52, 14.54)	0.099
Relative risk (95% confidence interval)	0.20 (0.03, 1.62)		



Supplementary Figure 1 Kaplan–Meier survival curve for exit-site infection



Supplementary Figure 2 Kaplan–Meier survival curve for catheter-related bloodstream infection
CRBSI, catheter-related bloodstream infection

Supplementary Table 2 Exit-site inflammatory score

Exit site inflammatory score	Mangostin (N=33)	Placebo (N=33)	p-value
Score 0	10 (30.3%)	5 (15.2%)	0.066
Score 1	10 (30.3%)	11 (33.3%)	
Score 2	10 (30.3%)	5 (15.2%)	
Score 3	2 (6.1%)	7 (21.2%)	
Score 4	1 (3%)	5 (15.2%)	

Supplementary Table 3 Duration of catheter use and reasons for catheter removal

	Mangostin (N=33)	Placebo (N=33)
- Mean catheter duration (days)	28.55	25.03
- Median catheter duration (days)	22	21
- Establishment of permanent vascular access (%)	25 (75.8)	21 (63.6)
- Catheter-related bloodstream infection (%)	1 (3)	4 (12.1)

- Exit site infection (%)	1 (3)	2 (6)
- Renal recovery (%)	0	3 (9.1)
- Scheduled replacement	3 (9.1)	1 (3.0)
- Others (%)	3 (9.1)	2 (6.1)